Sarah Cannon Research Institute/SCRI — Nashville, Tennessee

Sarah Cannon Research Institute/SCRI is a clinical research site located in Nashville, Tennessee, United States 37203.

Crixeo Clinical Trials Trust Score: 24/100 (FAILING). This profile has not yet been claimed by the site owner.

Sarah Cannon Research Institute/SCRI has participated in 33 clinical trials with 11 currently active.

Therapeutic areas: Breast Neoplasm, Neoplasm Metastasis, Metastatic Pancreatic Cancer.

Sponsors: Eli Lilly and Company, MBQ Pharma, Loxo Oncology, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Nashville

Browse all research sites in Tennessee · View every site in Nashville

Sponsor Feasibility Report

Trust Score: 24/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Sarah Cannon Research Institute/SCRI?

Sarah Cannon Research Institute/SCRI has a Crixeo Trust Score of 24/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Sarah Cannon Research Institute/SCRI conducted?

Sarah Cannon Research Institute/SCRI has 33 clinical trials on record, with 11 currently active. Their work covers Breast Neoplasm, Neoplasm Metastasis, Metastatic Pancreatic Cancer.

Is Sarah Cannon Research Institute/SCRI accredited by Crixeo Clinical Trials?

Sarah Cannon Research Institute/SCRI has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Sarah Cannon Research Institute/SCRI?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.